Pharmacokinetic studies in migraine: What questions should physicians ask?
Date
2004
Authors
Rolan, P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Current Pain and Headache Reports, 2004; 8(3):219-222
Statement of Responsibility
Conference Name
Abstract
Migraine is a benign self-limiting condition for which the objective of treatment is to maximize the patient’s quality of life by reducing the frequency of attacks and attenuating the pain and suffering of an individual attack as quickly and safely as possible. Evaluating the efficacy of antimigraine treatments, particularly those for the management of the acute attack, is relatively easy because acute symptomatic benefit is the criterion of success. For prophylaxis, therapeutic success generally is measured by relatively simple parameters such as attack frequency. Given that the clinical response to antimigraine therapies relatively is readily assessed by history, the role of more sophisticated investigations such as pharmacokinetic studies may not be immediately clear. This paper aims to provide clinicians with a guide to interpretation of such studies.
School/Discipline
Dissertation Note
Provenance
Description
Copyright © 2004 by Current Science Inc.